Mirvetuximab Soravtansine (Elahere)

Type: drug

Status: FDA Approved

Developer: ImmunoGen/AbbVie

Breakthrough Summary

No summary available.

Mechanism of Action

ADC targeting folate receptor alpha on ovarian cancer cells

Year: 2022+